Novartis Pharma AG: Sandoz Application for proposed biosimilar adalimumab's high concentration formulation accepted by EMA

Submission supported by comprehensive analytical and clinical data from new Phase I bridging pharmacokinetics studyAdalimumab's high-concentration 100 mg/mL formulation aims to provide an enhanced yet

Related Keywords

United States ,America ,Richard Jarvis ,Isabella Zinck ,Thomas Hungerbuehler ,Sandoz Hyrimoz ,Samir Shah ,Chris Lewis ,Sloan Simpson ,Florian Bieber ,Novartis Communications ,Instagram ,Linkedin ,Abbvie Biotechnology Ltd ,Twitter ,Novartis ,Exchange Commission ,European Medicines Agency ,Facebook ,Sandoz Global Communications ,Global Head Biopharmaceuticals Development ,European Commission ,Abbvie Biotechnology ,Dharma ,Sandoz ,Application ,Roposed ,Biosimilar ,Adalimumab ,Thigh ,Concentration ,Formulation ,Accepted ,